Hollencrest Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.2K | Buy |
881
+18
| +2% | +$471 | ﹤0.01% | 718 |
|
|
2026
Q1 | $24.2K | Hold |
863
| – | – | ﹤0.01% | 689 |
|
|
2025
Q4 | $21.5K | Hold |
863
| – | – | ﹤0.01% | 699 |
|
|
2025
Q3 | $22K | Sell |
863
-482
| -36% | -$11.9K | ﹤0.01% | 693 |
|
|
2025
Q2 | $32.6K | Hold |
1,345
| – | – | ﹤0.01% | 583 |
|
|
2025
Q1 | $34.1K | Sell |
1,345
-9
| -0.7% | -$236 | ﹤0.01% | 573 |
|
|
2024
Q4 | $35.9K | Sell |
1,354
-175
| -11% | -$4.75K | ﹤0.01% | 590 |
|
|
2024
Q3 | $44.2K | Sell |
1,529
-404
| -21% | -$11.8K | ﹤0.01% | 531 |
|
|
2024
Q2 | $54.1K | Buy |
1,933
+23
| +1% | +$633 | ﹤0.01% | 497 |
|
|
2024
Q1 | $53K | Sell |
1,910
-8,909
| -82% | -$247K | ﹤0.01% | 480 |
|
|
2023
Q4 | $311K | Buy |
10,819
+1
| +0% | +$30 | 0.03% | 242 |
|
|
2023
Q3 | $359K | Sell |
10,818
-201
| -2% | -$7.11K | 0.04% | 204 |
|
|
2023
Q2 | $404K | Sell |
11,019
-461
| -4% | -$17.9K | 0.04% | 201 |
|
|
2023
Q1 | $468K | Buy |
11,480
+8,063
| +236% | +$348K | 0.05% | 185 |
|
|
2022
Q4 | $175K | Buy |
+3,417
| New | +$164K | 0.02% | 270 |
|
|
2022
Q3 | – | Sell |
-6,178
| Closed | -$324K | – | 341 |
|
|
2022
Q2 | $324K | Buy |
6,178
+416
| +7% | +$21.2K | 0.04% | 201 |
|
|
2022
Q1 | $298K | Buy |
5,762
+154
| +3% | +$7.99K | 0.03% | 259 |
|
|
2021
Q4 | $331K | Buy |
5,608
+156
| +3% | +$7.73K | 0.03% | 259 |
|
|
2021
Q3 | $234K | Sell |
5,452
-1,339
| -20% | -$59.3K | 0.02% | 312 |
|
|
2021
Q2 | $266K | Sell |
6,791
-54,038
| -89% | -$2.1M | 0.02% | 292 |
|
|
2021
Q1 | $2.2M | Sell |
60,829
-12,502
| -17% | -$444K | 0.21% | 74 |
|
|
2020
Q4 | $2.7M | Sell |
73,331
-2,855
| -4% | -$105K | 0.28% | 60 |
|
|
2020
Q3 | $2.65M | Sell |
76,186
-521
| -0.7% | -$18.3K | 0.32% | 53 |
|
|
2020
Q2 | $2.38M | Buy |
76,707
+1,737
| +2% | +$59K | 0.32% | 53 |
|
|
2020
Q1 | $2.32M | Sell |
74,970
-12,397
| -14% | -$422K | 0.34% | 50 |
|
|
2019
Q4 | $3.25M | Sell |
87,367
-8,271
| -9% | -$295K | 0.36% | 46 |
|
|
2019
Q3 | $3.26M | Sell |
95,638
-3,291
| -3% | -$120K | 0.4% | 44 |
|
|
2019
Q2 | $4.07M | Sell |
98,929
-11,919
| -11% | -$473K | 0.51% | 34 |
|
|
2019
Q1 | $4.47M | Sell |
110,848
-373
| -0.3% | -$14.9K | 0.6% | 29 |
|
|
2018
Q4 | $4.61M | Buy |
111,221
+373
| +0.3% | +$15.5K | 0.69% | 30 |
|
|
2018
Q3 | $4.47M | Buy |
110,848
+503
| +0.5% | +$19.4K | 0.6% | 29 |
|
|
2018
Q2 | $3.8M | Buy |
110,345
+3,255
| +3% | +$111K | 0.5% | 38 |
|
|
2018
Q1 | $3.61M | Sell |
107,090
-6,041
| -5% | -$208K | 0.47% | 40 |
|
|
2017
Q4 | $3.89M | Buy |
113,131
+670
| +0.6% | +$22.8K | 0.51% | 39 |
|
|
2017
Q3 | $3.81M | Sell |
112,461
-6,811
| -6% | -$219K | 0.53% | 34 |
|
|
2017
Q2 | $3.8M | Buy |
119,272
+461
| +0.4% | +$14.5K | 0.57% | 32 |
|
|
2017
Q1 | $3.86M | Sell |
118,811
-8,829
| -7% | -$278K | 0.56% | 33 |
|
|
2016
Q4 | $3.93M | Sell |
127,640
-46,630
| -27% | -$1.42M | 0.59% | 33 |
|
|
2016
Q3 | $5.6M | Sell |
174,270
-3,525
| -2% | -$118K | 0.81% | 30 |
|
|
2016
Q2 | $5.94M | Sell |
177,795
-31,738
| -15% | -$1.01M | 0.92% | 24 |
|
|
2016
Q1 | $5.89M | Buy |
209,533
+790
| +0.4% | +$22.6K | 1% | 24 |
|
|
2015
Q4 | $6.39M | Buy |
208,743
+248
| +0.1% | +$7.8K | 1.13% | 20 |
|
|
2015
Q3 | $6.21M | Sell |
208,495
-9,887
| -5% | -$317K | 1.08% | 22 |
|
|
2015
Q2 | $6.95M | Sell |
218,382
-153,913
| -41% | -$5.02M | 1% | 27 |
|
|
2015
Q1 | $12.3M | Buy |
372,295
+2,314
| +0.6% | +$73.6K | 1.63% | 17 |
|
|
2014
Q4 | $10.9M | Sell |
369,981
-17,160
| -4% | -$492K | 1.44% | 19 |
|
|
2014
Q3 | $10.9M | Buy |
387,141
+29,715
| +8% | +$834K | 1.49% | 19 |
|
|
2014
Q2 | $10.1M | Buy |
357,426
+65,359
| +22% | +$1.86M | 1.35% | 21 |
|
|
2014
Q1 | $8.9M | Buy |
292,067
+11,132
| +4% | +$332K | 1.32% | 20 |
|
|
2013
Q4 | $8.16M | Buy |
+280,935
| New | +$8.18M | 1.33% | 19 |
|
Other funds holding PFE
Hollencrest Capital Management's PFE Position: Q2 2026 in Review
Hollencrest Capital Management increased its Pfizer (PFE) stake by 2.1% in Q2 2026, buying an estimated $471 and bringing the position to 881 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #718.
Hollencrest Capital Management first reported a position in PFE in Q4 2013 and has held it in 50 quarters since. The position peaked at $12.3M in Q1 2015. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Hollencrest Capital Management held 881 shares of Pfizer worth $21.2K as of Q2 2026.
- Hollencrest Capital Management bought 18 Pfizer shares in Q2 2026, an estimated $471.
- Pfizer made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #718 holding.
- Hollencrest Capital Management first reported a position in Pfizer in Q4 2013 and has held it in 50 quarters since.
- Hollencrest Capital Management's Pfizer position peaked at $12.3M in Q1 2015.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.